| Genomic hallmarks and structural variation in metastatic prostate cancer DA Quigley, HX Dang, SG Zhao, P Lloyd, R Aggarwal, JJ Alumkal, A Foye, ... Cell 174 (3), 758-769. e9, 2018 | 482 | 2018 |
| Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity A Zoubeidi, A Zardan, E Beraldi, L Fazli, R Sowery, P Rennie, C Nelson, ... Cancer research 67 (21), 10455-10465, 2007 | 289 | 2007 |
| The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate CancerBRN2 Is an AR-Suppressed Driver of NEPC JL Bishop, D Thaper, S Vahid, A Davies, K Ketola, H Kuruma, R Jama, ... Cancer discovery 7 (1), 54-71, 2017 | 278* | 2017 |
| PD-L1 is highly expressed in Enzalutamide resistant prostate cancer JL Bishop, A Sio, A Angeles, ME Roberts, AA Azad, KN Chi, A Zoubeidi Oncotarget 6 (1), 234, 2015 | 250 | 2015 |
| Cellular plasticity and the neuroendocrine phenotype in prostate cancer AH Davies, H Beltran, A Zoubeidi Nature Reviews Urology 15 (5), 271-286, 2018 | 241 | 2018 |
| Risk SNP-mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19 JT Hua, M Ahmed, H Guo, Y Zhang, S Chen, F Soares, J Lu, S Zhou, ... Cell 174 (3), 564-575. e18, 2018 | 232 | 2018 |
| The placental gene PEG10 promotes progression of neuroendocrine prostate cancer S Akamatsu, AW Wyatt, D Lin, S Lysakowski, F Zhang, S Kim, C Tse, ... Cell reports 12 (6), 922-936, 2015 | 222 | 2015 |
| Hsp27 Regulates Epithelial Mesenchymal Transition, Metastasis, and Circulating Tumor Cells in Prostate CancerRole of Hsp27 in EMT and Prostate Cancer Metastasis M Shiota, JL Bishop, KM Nip, A Zardan, A Takeuchi, T Cordonnier, ... Cancer research 73 (10), 3109-3119, 2013 | 211 | 2013 |
| Small heat shock proteins in cancer therapy and prognosis A Zoubeidi, M Gleave The international journal of biochemistry & cell biology 44 (10), 1646-1656, 2012 | 206 | 2012 |
| From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer AV Lapuk, C Wu, AW Wyatt, A McPherson, BJ McConeghy, S Brahmbhatt, ... The Journal of pathology 227 (3), 286-297, 2012 | 195 | 2012 |
| The Role of Lineage Plasticity in Prostate Cancer Therapy ResistanceLineage Plasticity in Prostate Cancer Resistance H Beltran, A Hruszkewycz, HI Scher, J Hildesheim, J Isaacs, EY Yu, ... Clinical cancer research 25 (23), 6916-6924, 2019 | 170 | 2019 |
| Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced CancerTargeting Clusterin in Cancer A Zoubeidi, K Chi, M Gleave Clinical Cancer Research 16 (4), 1088-1093, 2010 | 163 | 2010 |
| Clusterin mediates TGF-β–induced epithelial–mesenchymal transition and metastasis via Twist1 in prostate cancer cells M Shiota, A Zardan, A Takeuchi, M Kumano, E Beraldi, S Naito, ... Cancer research 72 (20), 5261-5272, 2012 | 158 | 2012 |
| Targeting the PI3K/Akt pathway in prostate cancer: challenges and opportunities P Toren, A Zoubeidi International journal of oncology 45 (5), 1793-1801, 2014 | 151 | 2014 |
| Clusterin Facilitates COMMD1 and I-κB Degradation to Enhance NF-κB Activity in Prostate Cancer CellsClusterin Activates the NF-κB Pathway A Zoubeidi, S Ettinger, E Beraldi, B Hadaschik, A Zardan, LWJ Klomp, ... Molecular Cancer Research 8 (1), 119-130, 2010 | 148 | 2010 |
| Clusterin knockdown using the antisense oligonucleotide OGX‐011 re‐sensitizes docetaxel‐refractory prostate cancer PC‐3 cells to chemotherapy RD Sowery, BA Hadaschik, AI So, A Zoubeidi, L Fazli, A Hurtado‐Coll, ... BJU international 102 (3), 389-397, 2008 | 144 | 2008 |
| Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression In VivoTargeting AKT Pathway and AR … C Thomas, F Lamoureux, C Crafter, BR Davies, E Beraldi, L Fazli, S Kim, ... Molecular cancer therapeutics 12 (11), 2342-2355, 2013 | 137 | 2013 |
| The DNA methylation landscape of advanced prostate cancer SG Zhao, WS Chen, H Li, A Foye, M Zhang, M Sjöström, R Aggarwal, ... Nature genetics 52 (8), 778-789, 2020 | 134 | 2020 |
| ONECUT2 is a driver of neuroendocrine prostate cancer H Guo, X Ci, M Ahmed, JT Hua, F Soares, D Lin, L Puca, A Vosoughi, ... Nature communications 10 (1), 278, 2019 | 134 | 2019 |
| The multifaceted roles of STAT3 signaling in the progression of prostate cancer JL Bishop, D Thaper, A Zoubeidi Cancers 6 (2), 829-859, 2014 | 127 | 2014 |
Martin GleaveProfessor of Urologic Sciences, University of British ColumbiaVerified email at ubc.ca
